Article in GEN Insight & Intelligence: Latest Biosimilar Guidance Raises More Questions. Quick FDA action just as unlikely as last year, when agency issued original policy advice.
July 9, 2013
Testifying before Congress in April, FDA Commissioner Margaret A. Hamburg, M.D., sought to reassure lawmakers: “We are developing a science-based process for bringing safe and effective biosimilar and interchangeable products to market, which should increase competition and create substantial savings for patients, healthcare providers, and insurers.” More than a year after issuing three draft guidances […]